Cullinan Therapeutics (CGEM) Insider Trading & Ownership $7.54 -0.07 (-0.92%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.56 +0.02 (+0.32%) As of 08/29/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cullinan Therapeutics (NASDAQ:CGEM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.16%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$665.44K Get CGEM Insider Trade Alerts Want to know when executives and insiders are buying or selling Cullinan Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Insider Buying and Selling by Quarter Cullinan Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/25/2025Jeffrey Alan JonesInsiderSell4,895$8.53$41,754.35 2/25/2025Nadim AhmedCEOSell12,529$8.53$106,872.37 1/6/2025Jennifer MichaelsonInsiderSell4,000$12.51$50,040.00 12/24/2024Nadim AhmedCEOSell8,400$11.87$99,708.00 12/18/2024Jennifer MichaelsonInsiderSell4,693$11.41$53,547.13 12/12/2024Jennifer MichaelsonInsiderSell3,489$12.52$43,682.28 11/5/2024Jennifer MichaelsonInsiderSell8,000$15.64$125,120.00 9/5/2024Jennifer MichaelsonInsiderSell8,000$18.09$144,720.00 (Data available from 1/1/2013 forward) CGEM Insider Trading Activity - Frequently Asked Questions Who is on Cullinan Therapeutics' Insider Roster? The list of insiders at Cullinan Therapeutics includes Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, and Nadim Ahmed. Learn more on insiders at CGEM. What percentage of Cullinan Therapeutics stock is owned by insiders? 7.16% of Cullinan Therapeutics stock is owned by insiders. Learn more on CGEM's insider holdings. Which Cullinan Therapeutics insiders have been selling company stock? The following insiders have sold CGEM shares in the last 24 months: Corrine Savill ($1,437,623.76), Jeffrey Alan Jones ($60,737.27), Jeffrey Trigilio ($34,633.62), Jennifer Michaelson ($2,184,150.49), and Nadim Ahmed ($246,053.65). How much insider selling is happening at Cullinan Therapeutics? Insiders have sold a total of 230,520 Cullinan Therapeutics shares in the last 24 months for a total of $3,963,198.79 sold. Cullinan Therapeutics Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Compensation: $1.16MDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Compensation: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Compensation: $763.73kMs. Mary Kay Fenton (Age 60)Chief Financial Officer Dr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations Officer More Insider Trading Tools from MarketBeat Related Companies Beam Therapeutics Insider Transactions Dyne Therapeutics Insider Transactions Apogee Therapeutics Insider Transactions Twist Bioscience Insider Transactions Travere Therapeutics Insider Transactions Biohaven Insider Transactions Immunocore Insider Transactions Cidara Therapeutics Insider Transactions Aurinia Pharmaceuticals Insider Transactions WAVE Life Sciences Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:CGEM) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
